Medexpress: Many experts emphasize that in recent years we have seen great progress in access to new therapies in hematooncology in Poland. Do you share these observations?
Prof. Krzysztof Giannopoulos: Yes. I think the reimbursement list that was announced in May completes the possibilities of therapies emerging in various areas. It's worth emphasizing that the path from the decision regarding the registration of a drug (first in the US, then in Europe, that is, also in Poland) and reimbursement is getting shorter and shorter. I would emphasize two aspects here. First, reimbursement decisions are broader, that is, very close to registration (we would strive for this, for the reason that, as we know, registrations are based on phase three studies, that is, studies of the highest scientific quality). As there is a benefit of a given new therapy, we physicians as practitioners should be able to offer this type of therapy to our patients. And the second element, which is very important, is the transition of drugs from the drug program to the chemotherapy catalog. And here the decisions of May 1 of this year expand the availability of modern therapy (lymphoma therapy) and complement the drug program. As one of the experts dealing with a specific area in oncolog...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
